Latest Asx News

Alterity Therapeutics is set to present compelling Phase 2 clinical trial results for ATH434 at the 2025 International Multiple System Atrophy Congress, highlighting slowed disease progression and biomarker engagement in MSA patients.

Global Data Centre Group updates its distribution guidance following the AirTrunk divestment, factoring in operational costs and risk reserves that temper immediate payouts.

SelfWealth Ltd has officially been acquired by Syfe’s holding company, with shareholders receiving $0.28 per share and the company set to delist from the ASX on May 8.

ARC Funds Limited has secured $1.4 million through equity and debt to complete a strategic acquisition of a majority stake in The Term Deposit Shop, expanding its footprint in Australia's term deposit market.

Tivan Limited’s shares have been suspended at the company’s request pending a major joint venture announcement and its response to an ASX compliance query.

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Echo IQ has raised $17.3 million through a strongly supported institutional placement to fund US commercialization and FDA approval efforts for its EchoSolv AI cardiology products.

SciDev Limited reported a robust Q3 FY25 with revenue rising 10% and EBITDA tripling, driven by strategic US market expansion and a landmark PFAS remediation contract despite ongoing market challenges.

Catalina Resources has successfully completed its entitlement and shortfall offer, raising over $2.27 million to strengthen its cash position and advance its diverse mineral projects.

Prospech Limited reports promising metallurgical test results from its Korsnäs Rare Earth Element resource, highlighting apatite as the dominant and well-liberated mineral. The company is fast-tracking bench-scale concentrate production and hydrometallurgical extraction to advance resource development.

Althea Group Holdings has agreed to sell its pharmaceutical assets to Tasmanian Botanics, enabling a strategic pivot towards the booming North American THC-infused beverage market.

Adavale Resources has identified a compelling new drill target at its Ashes Prospect through reprocessed geophysical data, supported by high-grade rock chip assays. The company is poised to commence maiden drilling in Q2 2025, aiming to unlock significant gold-copper-silver mineralisation.